Skye Bioscience has filed a notice of an exempt offering of securities to raise $40 Million in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Skye Bioscience is raising up to $40,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Punit Dhillon played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About Skye Bioscience
Skye Bioscience, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company’s lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy. It has license agreement with university of Mississippi. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. The company is headquartered in San Diego, California.
To learn more about Skye Bioscience, visit http://skyebioscience.com/
Contact:
Punit Dhillon, President and Chief Executive Officer
858-410-0266
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.